Sangmo Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sangmo Hong has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Cheol-Young Park
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
16 shared publications - Kyungdo Han
Soongsil University 5 Department of Statistics and Actuarial Science Seoul, Republic of Korea
13 shared publications Chang Beom Lee
Affiliation Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea
12 shared publicationsJung Hwan Park
Affiliation Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea
9 shared publications- Kyung-Soo Kim
Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine
8 shared publications Kyungdo Han
Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea
8 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0357017
Appendicular-to-trunk lean mass ratio resolves the height-based normalization paradox in low muscle mass and metabolic syndrome: A population-based cross-sectional study
Whether height-based normalization indices for appendicular lean mass (ALM) are metabolically neutral remains uncertain, because such indices may be influenced by adiposity. We evaluated ALM normalized to trunk lean mass (ALM/TLM) — both with bone mineral content excluded — as a normalization strategy potentially less susceptible to adiposity-related distortion. Using the Korea National Health and Nutrition Examination Survey 2008–2010, we analyzed 3,176 adults aged ≥65 years (1,373 men; 1,803 women) for body composition by dual-energy X-ray absorptiometry. Sex-specific Class I and Class II cut-offs were derived from a healthy young reference group aged 20–39 years (n = 3,727) at 1 SD and 2 SD below the young-adult mean. Metabolic syndrome (MetS) was defined by NCEP-ATP III criteria with population-specific waist cut-offs. Survey-weighted regression models were adjusted for age, smoking, alcohol, and physical activity. The appendicular skeletal muscle mass index (ASMI; ALM/height 2 ) correlated positively with fat mass index (FMI) (men r=+0.288; women r=+0.358; both p < 0.001), whereas ALM/TLM correlated negatively with FMI (men r=−0.199; women r=−0.243; both p < 0.001). ASMI Class I low muscle mass showed an inverse association with MetS (men odds ratio [OR] 0.496, 95% confidence interval [CI] 0.388–0.636; women OR 0.475, 95% CI 0.328–0.686). In contrast, ALM/TLM Class II showed positive associations with MetS (men OR 2.779, 95% CI 2.074–3.722; women OR 2.701, 95% CI 1.680–4.340; both p < 0.001). The inverse ALM/TLM–HOMA-IR association persisted after FMI adjustment (men β=−0.131, p < 0.001; women β=−0.065, p = 0.007). ASMI correlated positively with adiposity, while ASMI-defined low muscle mass was inversely associated with MetS, suggesting that ASMI may partly reflect body size/adiposity rather than relative muscle depletion alone; this inverse association should not be interpreted as protective. By contrast, ALM/TLM-defined low muscle mass showed consistently positive associations with MetS across adiposity strata, supporting further evaluation of ALM/TLM, although its clinical validity remains unestablished.
- 25 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0357017
Open AccessAppendicular-to-trunk lean mass ratio resolves the height-based normalization paradox in low muscle mass and metabolic syndrome: A population-based cross-sectional study
Whether height-based normalization indices for appendicular lean mass (ALM) are metabolically neutral remains uncertain, because such indices may be influenced by adiposity. We evaluated ALM normalized to trunk lean mass (ALM/TLM) — both with bone mineral content excluded — as a normalization strategy potentially less susceptible to adiposity-related distortion. Using the Korea National Health and Nutrition Examination Survey 2008–2010, we analyzed 3,176 adults aged ≥65 years (1,373 men; 1,803 women) for body composition by dual-energy X-ray absorptiometry. Sex-specific Class I and Class II cut-offs were derived from a healthy young reference group aged 20–39 years (n = 3,727) at 1 SD and 2 SD below the young-adult mean. Metabolic syndrome (MetS) was defined by NCEP-ATP III criteria with population-specific waist cut-offs. Survey-weighted regression models were adjusted for age, smoking, alcohol, and physical activity. The appendicular skeletal muscle mass index (ASMI; ALM/height 2 ) correlated positively with fat mass index (FMI) (men r=+0.288; women r=+0.358; both p < 0.001), whereas ALM/TLM correlated negatively with FMI (men r=−0.199; women r=−0.243; both p < 0.001). ASMI Class I low muscle mass showed an inverse association with MetS (men odds ratio [OR] 0.496, 95% confidence interval [CI] 0.388–0.636; women OR 0.475, 95% CI 0.328–0.686). In contrast, ALM/TLM Class II showed positive associations with MetS (men OR 2.779, 95% CI 2.074–3.722; women OR 2.701, 95% CI 1.680–4.340; both p < 0.001). The inverse ALM/TLM–HOMA-IR association persisted after FMI adjustment (men β=−0.131, p < 0.001; women β=−0.065, p = 0.007). ASMI correlated positively with adiposity, while ASMI-defined low muscle mass was inversely associated with MetS, suggesting that ASMI may partly reflect body size/adiposity rather than relative muscle depletion alone; this inverse association should not be interpreted as protective. By contrast, ALM/TLM-defined low muscle mass showed consistently positive associations with MetS across adiposity strata, supporting further evaluation of ALM/TLM, although its clinical validity remains unestablished.
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1905093
Behavioral and health-factor domains of Life’s Essential 8 in advanced cardiovascular-kidney-metabolic syndrome among Korean adults: a nationally representative cross-sectional analysis
Introduction: Life’s Essential 8 (LE8) summarizes cardiovascular health through four behavioral and four health-factor metrics, whereas cardiovascular-kidney-metabolic (CKM) syndrome staging characterizes disease burden and severity. Whether the two LE8 domains associate differently with advanced CKM syndrome in an Asian population remains unclear. Methods: We analyzed 17,351 Korean adults aged 20–79 years from the Korea National Health and Nutrition Examination Survey (2019–2021 and 2024) using a Korean-adapted, American Heart Association-aligned CKM framework incorporating Korean adiposity thresholds, the Korean cardiovascular risk equation, and Korean-specific LE8 body mass index scoring. Advanced CKM (Stage ≥ 3) was the primary outcome. Survey-weighted logistic regression estimated adjusted odds ratios (aORs) per 10-point LE8 increment, with prespecified sequential CKM-spectrum restriction, four outcome definitions, and medication-stratified lipid analyses. Results: The weighted prevalence of advanced CKM was 4.13% (931 cases). Each 10-point higher LE8 score was associated with lower odds of advanced CKM (aOR 0.765, 95% confidence interval [CI] 0.716–0.818). Behavioral and health-factor subscores remained independently associated after mutual adjustment. Across sequential CKM-spectrum restrictions, the behavioral association remained stable (aORs 0.879–0.897), whereas the health-factor association attenuated to non-significance at the most restricted level (aOR 0.998). Participants in the lowest LE8 quintile had 3.32-fold higher odds than those in the highest quintile (95% CI 2.30–4.80). Discussion: Higher LE8-defined cardiovascular health was inversely associated with advanced CKM; behavioral-domain associations remained stable across CKM-spectrum restriction, whereas health-factor associations require cautious interpretation owing to stage-definition overlap and treatment-related score modification. The cross-sectional design precludes causal inference.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1905093
Open AccessBehavioral and health-factor domains of Life’s Essential 8 in advanced cardiovascular-kidney-metabolic syndrome among Korean adults: a nationally representative cross-sectional analysis
Introduction: Life’s Essential 8 (LE8) summarizes cardiovascular health through four behavioral and four health-factor metrics, whereas cardiovascular-kidney-metabolic (CKM) syndrome staging characterizes disease burden and severity. Whether the two LE8 domains associate differently with advanced CKM syndrome in an Asian population remains unclear. Methods: We analyzed 17,351 Korean adults aged 20–79 years from the Korea National Health and Nutrition Examination Survey (2019–2021 and 2024) using a Korean-adapted, American Heart Association-aligned CKM framework incorporating Korean adiposity thresholds, the Korean cardiovascular risk equation, and Korean-specific LE8 body mass index scoring. Advanced CKM (Stage ≥ 3) was the primary outcome. Survey-weighted logistic regression estimated adjusted odds ratios (aORs) per 10-point LE8 increment, with prespecified sequential CKM-spectrum restriction, four outcome definitions, and medication-stratified lipid analyses. Results: The weighted prevalence of advanced CKM was 4.13% (931 cases). Each 10-point higher LE8 score was associated with lower odds of advanced CKM (aOR 0.765, 95% confidence interval [CI] 0.716–0.818). Behavioral and health-factor subscores remained independently associated after mutual adjustment. Across sequential CKM-spectrum restrictions, the behavioral association remained stable (aORs 0.879–0.897), whereas the health-factor association attenuated to non-significance at the most restricted level (aOR 0.998). Participants in the lowest LE8 quintile had 3.32-fold higher odds than those in the highest quintile (95% CI 2.30–4.80). Discussion: Higher LE8-defined cardiovascular health was inversely associated with advanced CKM; behavioral-domain associations remained stable across CKM-spectrum restriction, whereas health-factor associations require cautious interpretation owing to stage-definition overlap and treatment-related score modification. The cross-sectional design precludes causal inference.
- Open Access
- 24 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (6) , 4949-4960
Waist‐to‐Height Ratio and the Risk of Cardiovascular Outcomes and Mortality in Type 2 Diabetes With and Without Abdominal Obesity
Aim: Waist‐to‐height ratio (WHtR) has been suggested as a superior marker of cardiometabolic risk compared to waist circumference (WC), but evidence in type 2 diabetes mellitus (T2DM) remains limited. Materials and Methods: A population‐based cohort of 2 076 104 patients with T2DM who underwent the Korean national health checkup between 2015 and 2016 were followed until 2022. Multivariable Cox proportional hazards regression was performed to analyse the association between WHtR and the risk of incident myocardial infarction, stroke and mortality. Restricted cubic spline analyses were performed to evaluate continuous dose–response relationships, with additional stratification by abdominal obesity. Results: During follow‐up, 125 493 deaths (6.0%), 56 280 myocardial infarctions (2.7%) and 62 938 strokes (3.0%) occurred. WHtR showed increasing association with the risk of myocardial infarction and stroke, and a U‐shaped association with all‐cause mortality. Individuals with both abdominal obesity and WHtR ≥ 0.5 had higher risks of myocardial infarction ( HR 1.12, 95% CI 1.07–1.17), stroke ( HR 1.18, 95% CI 1.15–1.21) and mortality ( HR 1.20, 95% CI 1.16–1.25). In those without abdominal obesity, WHtR ≥ 0.5 was also associated with increased cardiovascular risks but slightly lower mortality. In contrast, those with abdominal obesity but normal WHtR had no significantly increased risks for any outcomes. The associations were stronger in younger adults and individuals with new‐onset T2DM for cardiovascular outcomes, and in those with long‐standing T2DM for mortality. Conclusions: WHtR was independently associated with cardiovascular outcomes and mortality in individuals with T2DM, including those without abdominal obesity. This simple measurement may provide additional information beyond WC for evaluating cardiometabolic risk in this population.
- 24 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (6) , 4949-4960
Open AccessWaist‐to‐Height Ratio and the Risk of Cardiovascular Outcomes and Mortality in Type 2 Diabetes With and Without Abdominal Obesity
Aim: Waist‐to‐height ratio (WHtR) has been suggested as a superior marker of cardiometabolic risk compared to waist circumference (WC), but evidence in type 2 diabetes mellitus (T2DM) remains limited. Materials and Methods: A population‐based cohort of 2 076 104 patients with T2DM who underwent the Korean national health checkup between 2015 and 2016 were followed until 2022. Multivariable Cox proportional hazards regression was performed to analyse the association between WHtR and the risk of incident myocardial infarction, stroke and mortality. Restricted cubic spline analyses were performed to evaluate continuous dose–response relationships, with additional stratification by abdominal obesity. Results: During follow‐up, 125 493 deaths (6.0%), 56 280 myocardial infarctions (2.7%) and 62 938 strokes (3.0%) occurred. WHtR showed increasing association with the risk of myocardial infarction and stroke, and a U‐shaped association with all‐cause mortality. Individuals with both abdominal obesity and WHtR ≥ 0.5 had higher risks of myocardial infarction ( HR 1.12, 95% CI 1.07–1.17), stroke ( HR 1.18, 95% CI 1.15–1.21) and mortality ( HR 1.20, 95% CI 1.16–1.25). In those without abdominal obesity, WHtR ≥ 0.5 was also associated with increased cardiovascular risks but slightly lower mortality. In contrast, those with abdominal obesity but normal WHtR had no significantly increased risks for any outcomes. The associations were stronger in younger adults and individuals with new‐onset T2DM for cardiovascular outcomes, and in those with long‐standing T2DM for mortality. Conclusions: WHtR was independently associated with cardiovascular outcomes and mortality in individuals with T2DM, including those without abdominal obesity. This simple measurement may provide additional information beyond WC for evaluating cardiometabolic risk in this population.
- Open Access
- 1 January 2026
- Published by XMLink in Electrolytes & Blood Pressure
- Vol. 24 (3) , 205-208
From Specialty Silos to Integrated Care: A Korean Initiative for Cardiovascular-Kidney-Metabolic Health
Chung S, et al. Electrolyte Blood Press. 2026 Sep;24(3):205-208. https://doi.org/10.5049/EBP.2026.24.e16
- 1 January 2026
- Published by XMLink in Electrolytes & Blood Pressure
- Vol. 24 (3) , 205-208
Open AccessFrom Specialty Silos to Integrated Care: A Korean Initiative for Cardiovascular-Kidney-Metabolic Health
Chung S, et al. Electrolyte Blood Press. 2026 Sep;24(3):205-208. https://doi.org/10.5049/EBP.2026.24.e16
- Open Access
- 1 November 2025
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 49 (6) , 1308-1317
Association of Systolic and Diastolic Blood Pressure with the Risk of End-Stage Renal Disease in Older Type 2 Diabetes Mellitus Patients without Cardiovascular Disease: A Nationwide Population-Based Study
Background: There is insufficient evidence to determine a precise blood pressure target in older adults with diabetes mellitus. In this study, we evaluated the potential relationship between blood pressure levels and end-stage renal disease (ESRD) in older type 2 diabetes mellitus (T2DM) patients without ESRD using a nationwide longitudinal population dataset.Methods: We performed a retrospective, observational, cohort study including 267,156 older (≥65 years old) patients with T2DM and without ESRD from 2009 to 2018 based on the National Health Information Database. We divided the participants into eight groups based on their systolic blood pressure (SBP) and diastolic blood pressure (DBP). The primary outcome was ESRD. All outcomes were analyzed using Cox proportional hazards regression analysis while controlling for baseline covariates.Results: During a median follow-up of 7.26 years, the incidence rate of ESRD was 2.03 per 1,000 person-years. In multivariable Cox proportional hazard modeling, the risk of the primary outcome was the lowest in groups with an SBP of 100–119 mm Hg and DBP of <80 mm Hg. In subgroup analysis according to the use of hypertension medication, there was a significant difference in DBP (P for interaction=0.026) but no difference in SBP (P for interaction=0.247). The risk of ESRD was the lowest in patients with an SBP of 110–129 mm Hg taking hypertension medication and the highest in the group with an SBP of ≥160 mm Hg.Conclusion: Maintaining blood pressure at less than 120/80 mm Hg might prevent progression to ESRD in older T2DM patients without cardiovascular disease.
- 1 November 2025
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 49 (6) , 1308-1317
Open AccessAssociation of Systolic and Diastolic Blood Pressure with the Risk of End-Stage Renal Disease in Older Type 2 Diabetes Mellitus Patients without Cardiovascular Disease: A Nationwide Population-Based Study
Background: There is insufficient evidence to determine a precise blood pressure target in older adults with diabetes mellitus. In this study, we evaluated the potential relationship between blood pressure levels and end-stage renal disease (ESRD) in older type 2 diabetes mellitus (T2DM) patients without ESRD using a nationwide longitudinal population dataset.Methods: We performed a retrospective, observational, cohort study including 267,156 older (≥65 years old) patients with T2DM and without ESRD from 2009 to 2018 based on the National Health Information Database. We divided the participants into eight groups based on their systolic blood pressure (SBP) and diastolic blood pressure (DBP). The primary outcome was ESRD. All outcomes were analyzed using Cox proportional hazards regression analysis while controlling for baseline covariates.Results: During a median follow-up of 7.26 years, the incidence rate of ESRD was 2.03 per 1,000 person-years. In multivariable Cox proportional hazard modeling, the risk of the primary outcome was the lowest in groups with an SBP of 100–119 mm Hg and DBP of <80 mm Hg. In subgroup analysis according to the use of hypertension medication, there was a significant difference in DBP (P for interaction=0.026) but no difference in SBP (P for interaction=0.247). The risk of ESRD was the lowest in patients with an SBP of 110–129 mm Hg taking hypertension medication and the highest in the group with an SBP of ≥160 mm Hg.Conclusion: Maintaining blood pressure at less than 120/80 mm Hg might prevent progression to ESRD in older T2DM patients without cardiovascular disease.
- Open Access
- 31 August 2025
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 40 (4) , 517-522
From Old to New: A Comprehensive Review of Obesity Diagnostic Criteria and Their Implications
Obesity is a chronic, multifactorial disease that imposes significant health burdens worldwide. Although body mass index (BMI) is widely used for its simplicity and utility at the population level, it fails to capture critical clinical aspects, including body composition, fat distribution, metabolic health, and functional impairment. This review explores the limitations of current BMI-based diagnostic criteria for obesity and introduces a new definition and diagnostic framework proposed by the Commission on Clinical Obesity. The new criteria redefine obesity using clinical and biological markers and distinguish between clinical and preclinical obesity based on functional consequences and risk stratification. This approach aims to facilitate more accurate diagnoses, individualized treatment, and evidence-based health policies, while also addressing issues such as weight stigma and overdiagnosis. Further research is needed to validate this model and support its integration into clinical practice.
- 31 August 2025
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 40 (4) , 517-522
Open AccessFrom Old to New: A Comprehensive Review of Obesity Diagnostic Criteria and Their Implications
Obesity is a chronic, multifactorial disease that imposes significant health burdens worldwide. Although body mass index (BMI) is widely used for its simplicity and utility at the population level, it fails to capture critical clinical aspects, including body composition, fat distribution, metabolic health, and functional impairment. This review explores the limitations of current BMI-based diagnostic criteria for obesity and introduces a new definition and diagnostic framework proposed by the Commission on Clinical Obesity. The new criteria redefine obesity using clinical and biological markers and distinguish between clinical and preclinical obesity based on functional consequences and risk stratification. This approach aims to facilitate more accurate diagnoses, individualized treatment, and evidence-based health policies, while also addressing issues such as weight stigma and overdiagnosis. Further research is needed to validate this model and support its integration into clinical practice.
- Open Access
- 28 February 2025
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 40 (1) , 1-9
Long-Term Prognosis and Systemic Impact of Acromegaly: Analyses Utilizing Korean National Health Insurance Data
Acromegaly is a rare endocrine disorder caused by excessive growth hormone secretion. Its low prevalence poses challenges in studying its long-term prognosis and systemic effects. To address this research gap, we conducted five studies using nationwide cohort data from the Korean National Health Insurance Database (NHID). This review consolidates the findings of these studies, which examined various long-term effects of acromegaly. The results demonstrated significant associations between acromegaly and increased mortality, a higher prevalence of mortality, cardiovascular outcomes, neurodegenerative diseases, depression, end-stage kidney disease, respiratory complications, specifically bronchiectasis, spine & hip fracture, and malignancy. These findings highlight the critical need for early diagnosis, comprehensive care, and long-term monitoring, and underscore the importance of a multidisciplinary approach in managing acromegaly.
- 28 February 2025
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 40 (1) , 1-9
Open AccessLong-Term Prognosis and Systemic Impact of Acromegaly: Analyses Utilizing Korean National Health Insurance Data
Acromegaly is a rare endocrine disorder caused by excessive growth hormone secretion. Its low prevalence poses challenges in studying its long-term prognosis and systemic effects. To address this research gap, we conducted five studies using nationwide cohort data from the Korean National Health Insurance Database (NHID). This review consolidates the findings of these studies, which examined various long-term effects of acromegaly. The results demonstrated significant associations between acromegaly and increased mortality, a higher prevalence of mortality, cardiovascular outcomes, neurodegenerative diseases, depression, end-stage kidney disease, respiratory complications, specifically bronchiectasis, spine & hip fracture, and malignancy. These findings highlight the critical need for early diagnosis, comprehensive care, and long-term monitoring, and underscore the importance of a multidisciplinary approach in managing acromegaly.
- Open Access
- 17 October 2024
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024083
Sex-specific associations between dietary legume subtypes and type 2 diabetes in a prospective cohort study
OBJECTIVES: Dietary soy, known for its high phytoestrogen content, has been suggested to exhibit a sex-specific association with type 2 diabetes. However, evidence regarding the sex-specific associations of different legume subtypes with type 2 diabetes remains scarce. We aimed to evaluate whether habitual consumption of soy and non-soy legumes (beans and peanuts) was prospectively and sex-specifically associated with the risk of type 2 diabetes incidence, taking into considering significant sex-specific genetic factors beyond legume consumption.METHODS: A total of 16,666 participants (96,945 person-years) were followed and 945 incident cases were observed. Cumulative intake of legume subtypes was calculated using a food frequency questionnaire administered at baseline and during the revisit surveys.RESULTS: Non-soy legumes are inversely associated with type 2 diabetes in both men and women. Dietary soy intake, however, demonstrated a unilaterally interacting sex-specific association with type 2 diabetes risk (pinteraction for sex=0.017). Specifically, there was a significant inverse association with type 2 diabetes risk in women (incidence rate ratio, 0.66; 95% confidence interval, 0.48 to 0.80; ptrend=0.007), but no such association was observed in men. This sex-specific association persisted and even appeared antagonistic in minor allele carriers of 2 novel single nucleotide polymorphisms, rs10196939 (LRRTM4) and rs11750158 (near GFPT2) (pinteraction for sex=0.001 and 0.011, respectively).CONCLUSIONS: Habitual consumption of legumes shows protective impacts against type 2 diabetes, although these benefits vary by sex. Non-soy legumes provide health advantages for both men and women, whereas soy consumption seems to be beneficial exclusively for women.
- 17 October 2024
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024083
Open AccessSex-specific associations between dietary legume subtypes and type 2 diabetes in a prospective cohort study
OBJECTIVES: Dietary soy, known for its high phytoestrogen content, has been suggested to exhibit a sex-specific association with type 2 diabetes. However, evidence regarding the sex-specific associations of different legume subtypes with type 2 diabetes remains scarce. We aimed to evaluate whether habitual consumption of soy and non-soy legumes (beans and peanuts) was prospectively and sex-specifically associated with the risk of type 2 diabetes incidence, taking into considering significant sex-specific genetic factors beyond legume consumption.METHODS: A total of 16,666 participants (96,945 person-years) were followed and 945 incident cases were observed. Cumulative intake of legume subtypes was calculated using a food frequency questionnaire administered at baseline and during the revisit surveys.RESULTS: Non-soy legumes are inversely associated with type 2 diabetes in both men and women. Dietary soy intake, however, demonstrated a unilaterally interacting sex-specific association with type 2 diabetes risk (pinteraction for sex=0.017). Specifically, there was a significant inverse association with type 2 diabetes risk in women (incidence rate ratio, 0.66; 95% confidence interval, 0.48 to 0.80; ptrend=0.007), but no such association was observed in men. This sex-specific association persisted and even appeared antagonistic in minor allele carriers of 2 novel single nucleotide polymorphisms, rs10196939 (LRRTM4) and rs11750158 (near GFPT2) (pinteraction for sex=0.001 and 0.011, respectively).CONCLUSIONS: Habitual consumption of legumes shows protective impacts against type 2 diabetes, although these benefits vary by sex. Non-soy legumes provide health advantages for both men and women, whereas soy consumption seems to be beneficial exclusively for women.
- Open Access
- 18 July 2024
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-11
Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study
Background: The beneficial effects of fenofibrate on atherosclerotic cardiovascular disease (ASCVD) outcomes in patients with diabetes and statin treatment are unclear. We investigated the effects of fenofibrate on all-cause mortality and ASCVD in patients with diabetes, high triglyceride (TG) levels and statin treatment. Methods: We performed a nationwide propensity-score matched (1:1) cohort study using data from the National Health Information Database in the Republic of Korea from 2010 to 2017. The study included 110,723 individuals with diabetes, TG levels ≥ 150 mg/dL, and no prior diagnoses of ASCVD who used statins and fenofibrate, and an equal matched number of similar patients who used statins alone (control group). The study outcomes included newly diagnosed myocardial infarction (MI), stroke, both (MI and/or stroke), and all-cause mortality. Results: Over a mean 4.03-year follow-up period, the hazard ratios (HR) for outcomes in the fenofibrate group in comparison to the control group were 0.878 [95% confidence interval (CI) 0.827–0.933] for MI, 0.901 (95% CI 0.848–0.957) for stroke, 0.897 (95% CI 0.858–0.937) for MI and/or stroke, and 0.716 (95% CI 0.685–0.749) for all-cause death. These beneficial effects of fenofibrate were consistent in the subgroup with TG 150–199 mg/dL but differed according to low-density lipoprotein cholesterol (LDL-C) levels. Conclusion: In this nationwide propensity-score matched cohort study involving individuals with diabetes and TG ≥ 150 mg/dL, the risk of all-cause death and ASCVD was significantly lower with fenofibrate use in conjunction with statin treatment compared to statin treatment alone. However, this finding was significant only in individuals with relatively high LDL-C levels. Graphical
- 18 July 2024
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-11
Open AccessFenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study
Background: The beneficial effects of fenofibrate on atherosclerotic cardiovascular disease (ASCVD) outcomes in patients with diabetes and statin treatment are unclear. We investigated the effects of fenofibrate on all-cause mortality and ASCVD in patients with diabetes, high triglyceride (TG) levels and statin treatment. Methods: We performed a nationwide propensity-score matched (1:1) cohort study using data from the National Health Information Database in the Republic of Korea from 2010 to 2017. The study included 110,723 individuals with diabetes, TG levels ≥ 150 mg/dL, and no prior diagnoses of ASCVD who used statins and fenofibrate, and an equal matched number of similar patients who used statins alone (control group). The study outcomes included newly diagnosed myocardial infarction (MI), stroke, both (MI and/or stroke), and all-cause mortality. Results: Over a mean 4.03-year follow-up period, the hazard ratios (HR) for outcomes in the fenofibrate group in comparison to the control group were 0.878 [95% confidence interval (CI) 0.827–0.933] for MI, 0.901 (95% CI 0.848–0.957) for stroke, 0.897 (95% CI 0.858–0.937) for MI and/or stroke, and 0.716 (95% CI 0.685–0.749) for all-cause death. These beneficial effects of fenofibrate were consistent in the subgroup with TG 150–199 mg/dL but differed according to low-density lipoprotein cholesterol (LDL-C) levels. Conclusion: In this nationwide propensity-score matched cohort study involving individuals with diabetes and TG ≥ 150 mg/dL, the risk of all-cause death and ASCVD was significantly lower with fenofibrate use in conjunction with statin treatment compared to statin treatment alone. However, this finding was significant only in individuals with relatively high LDL-C levels. Graphical